Tegaserod
CAS No. 145158-71-0
Tegaserod ( —— )
产品货号. M35455 CAS No. 145158-71-0
Tegaserod 是一种口服有效的 5-羟色胺受体 4 (HTR4; 5-HT4R) 激动剂和 5-HT2B 受体拮抗剂。Tegaserod 对人重组 5-HT2A、5-HT2B 和 5-HT2C 受体的 pKis 分别为 7.5、8.4 和 7.0。Tegaserod 导致肿瘤细胞凋亡,减弱 PI3K/Akt/mTOR 信号传导并降低 S6 磷酸化。Tegaserod 具有抗肿瘤活性,同时具有用于肠易激综合征 (IBS) 研究的潜力。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Tegaserod
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Tegaserod 是一种口服有效的 5-羟色胺受体 4 (HTR4; 5-HT4R) 激动剂和 5-HT2B 受体拮抗剂。Tegaserod 对人重组 5-HT2A、5-HT2B 和 5-HT2C 受体的 pKis 分别为 7.5、8.4 和 7.0。Tegaserod 导致肿瘤细胞凋亡,减弱 PI3K/Akt/mTOR 信号传导并降低 S6 磷酸化。Tegaserod 具有抗肿瘤活性,同时具有用于肠易激综合征 (IBS) 研究的潜力。
-
产品描述Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research.
-
体外实验Apoptosis Analysis Cell Line:A375, RPMI-7951 (RPMI), SH4, B16F10, MeWo and MEL-JUSO Concentration:3, 5 μM Incubation Time:24, 48, 72 hResult:There was a significant time and dose-dependent increase in apoptosis in all cell lines.Western Blot Analysis Cell Line:RPMI, SH4 and B16F10 cells Concentration:3, 5 μM Incubation Time:8 or 18?h Result:Decreased phosphorylation of the kinase directly upstream of S6, p70 S6 at Thr421/Ser424.
-
体内实验Animal Model:C57BL/6?J mice were subcutaneously injected with B16F10 cells Dosage:5?mg/kg Administration:Administered intraperitoneally (i.p.) daily for five consecutive days Result:Treatment significantly decreased tumor growth and resulted in only slight decreases in weight following treatment.Animal Model:Female C57BLKS/J db/db miceDosage:0.1, 0.5, 1.0, 2.0 mg/kg Administration:IP 15 min prior to gastric loading Result: Produced a dramatic decrease in the fraction of the meal remaining in the stomach for doses as low as 0.1 mg/kg (0.1 mg/kg). Accelerated gastric emptying, with a reduction of nearly 80% in the fraction remaining at 30 min (P < 0.0001) (0.1 mg/kg).Induced a significant decrease in the gastric emptying rate as the amount of the meal remaining at 30 min was significantly greater (2.0 mg/kg).Resulted in inhibition of tegaserod-induced increased gastric emptying (0.1 mg/kg).
-
同义词——
-
通路GPCR/G Protein
-
靶点5-HT Receptor
-
受体5-HT Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number145158-71-0
-
分子量301.39
-
分子式C16H23N5O
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 50 mg/mL (165.90 mM; 超声助溶 )
-
SMILESN=C(NN=CC1=CNC=2C=CC(OC)=CC12)NCCCCC
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wei Liu, et al. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2020 Feb 21;39(1):38.?
产品手册
关联产品
-
F-11440
一种有效的选择性 5-HT1A 受体激动剂,Ki 为 4.8 nM,pKi 为 8.33。
-
ATC 0175 hydrochlori...
ATC0175 是一种有效的、选择性和口服活性的黑色素浓缩激素 1 受体拮抗剂,MCH1R 和 MCH2R 的 IC50s 分别为 13.5,>10000 nM。ATC0175 在动物模型中显示出抗抑郁作用和抗焦虑作用。ATC0175 具有研究抑郁症和/或焦虑症的潜力。
-
(Iso)-Landipirdine
(Iso)-Landipirdine((Iso)-RO5025181) is a selective and potent 5-HT6R antagonist. (Iso)-Landipirdine has a significant effect on the hERG pharmacophore and can be used to study neurological disorders in the Alzheimer's disease class.
021-51111890
购物车()
sales@molnova.cn

